Skip to main content

Cravatt Benjamin's Form 4 filing

Kyntra Bio, Inc. (KYNB) · filed Jun 9, 2023

Accession no.
0001209191-23-036081
Filed
Jun 9, 2023
Trade date
Jun 7-9, 2023
Filing delay
2 days
Rule 10b5-1 plan
Checked

This filing lists 3 non-derivative transactions and 1 derivative transaction. Open-market sales total $67.7K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Cravatt BenjaminCIK 0001819573Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Jun 7, 2023Common StockAGrant or awardAcquired+8,289$0.00$032,680Direct
Jun 9, 2023Common StockSSaleDisposed−1,766$16.75F3−$29,580.530,914Direct
Jun 9, 2023Common StockSSaleDisposed−2,178$17.51F4−$38,136.7828,736Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Jun 7, 2023Common StockAGrant or awardAcquired+12,666$0.00$012,666Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

F3

Price reported is a weighted-average sales price. The shares were sold at prices ranging from $16.16 to $17.13. The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.

Referenced by the price of 1 transaction in Table I.

F4

Price reported is a weighted-average sales price. The shares were sold at prices ranging from $17.40 to $17.72. The Reporting Person will provide upon request to the SEC, the Issuer or security holder of the Issuer, full information regarding the number of shares sold at each separate price.

Referenced by the price of 1 transaction in Table I.

Read the full filing on SEC EDGAR (opens in a new tab)